Article Text

other Versions

Download PDFPDF
Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia
  1. Yiqin Wang1,
  2. Rong Zhou1,
  3. Haibo Wang2,
  4. Huixin Liu3 and
  5. Jianliu Wang1
  1. 1 Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing, China
  2. 2 Peking University Clinical Research Institute, Beijing, China
  3. 3 Department of Clinical Epidemiology, Peking University People's Hospital, Beijing, China
  1. Correspondence to Jianliu Wang, Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing 100044, China; wangjianliu1203{at}163.com

Abstract

Objective Fertility preservation is an option for selected patients with endometrial hyperplasia or cancer. This study aimed to evaluate whether duration of treatment impacts the oncologic and reproductive outcomes.

Methods We retrospectively reviewed patients diagnosed with endometrial cancer/atypical endometrial hyperplasia who underwent fertility-sparing treatment from January 2012 to December 2016. As the duration of treatment required by the patients was different, the patients who achieved a complete response were grouped according to the treatment duration as groups A (≤6 months), B (6–9 months), and C (>9 months).

Results With the prolongation of treatment duration from 6 months to 9 months to >9 months, the accumulative complete response rates for 67 patients were 58%, 76%, and 95.5%, respectively. Among groups A, B, and C there was no significant difference in the relapse rates (21.1%, 25%, and 36.4%, respectively, p=0.60) or the median time interval to relapse (14, 13, and 13.5 months, respectively, p=0.90). Maintenance treatment was an independent protective factor for recurrence (p=0.001), while the complication of diabetes was an independent risk factor for recurrence (p=0.03). Fertility rates (31%, 18.2%, and 62.5%, respectively, p=0.12) and the time interval to pregnancy (14, 13, and 8 months, respectively, p=0.67) were not significantly different among the three groups. Assisted reproductive technology was positively associated with a higher pregnancy rate (p=0.02) and a body mass index ≥25 kg/m2 was negatively associated with the pregnancy rate (p=0.047).

Conclusions Longer treatment duration was associated with higher rates of complete response. Longer treatment duration (>9 months) was not associated with a decrease in success rates of pregnancy.

  • endometrial cancer
  • atypical endometrial hyperplasia
  • fertility-preserving
  • progestin
  • treatment duration

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • YW and RZ are joint senior authors.

  • YW and RZ contributed equally.

  • Funding This study was supported by the National Key Technology R&D Program (No. 2015BAI13B06) and the National Natural Science Foundation of China (grant 81672571).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned, externally peer reviewed.